°í°´¼¾ÅÍ

º¸µµÀÚ·á ¹× °øÁö»çÇ×

·è»ç ¹ÙÀÌ¿À ùȯÀÚ Åõ¾à º¸µµÀÚ·á 2022-06-15

·è»ç¹ÙÀÌ¿À °Ç¼ºÈ²¹Ýº¯¼º Ä¡·áÁ¦ °³¹ß ÀÓ»ó Phase1/2a ùȯÀÚ Åõ¾à

https://www.businesswire.com/news/home/20220524005126/en/

https://www.biospace.com/article/releases/luxa-bio-announces-first-participant-dosed-in-phase-1-2a-clinical-trial-of-adult-rpesc-rpe-4w-for-dry-age-related-macular-degeneration/

https://finance.yahoo.com/news/luxa-bio-announces-first-participant-120000860.html
 

https://www.fightingblindness.org/research/luxa-doses-first-participant-in-clinical-trial-of-rpe-stem-cells-for-dry-amd-patients-260

https://pharma-trend.com/en/luxa-bio-announces-first-participant-dosed-in-phase-1-2a-clinical-trial-of-adult-rpesc-rpe-4w-for-dry-age-related-macular-degeneration/
 

https://www.iqstock.news/n/luxa-bio-announces-participant-dosed-phase-2a-clinical-trial-adult-rpesc-rpe-3944173/